What distinguishes GHRP-6 from GHRP-2 in GHS-R1a receptor research models?
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) and GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2) are structurally related hexapeptides both studied as GHS-R1a agonists, differing in the first two amino acid positions. Comparative research has examined these structural differences for their effects on receptor binding affinity, selectivity, and downstream signalling intensity, making both compounds standard reference tools in comparative GHRP pharmacology research. What receptor binding assays are used to characterise GHRP-6's GHS-R1a selectivity profile?
Radioligand displacement assays and cell-based functional assays in GHS-R1a-expressing cell lines — measuring downstream readouts such as intracellular calcium mobilization and cAMP accumulation — are standard methods for characterising GHRP-6's receptor binding affinity and functional potency, typically run in parallel with GHRP-2 and other GHS-R1a reference ligands to establish comparative selectivity profiles. How does the single vial format compare to the 10-vial KIT format for experimental protocol planning?
The single 5mg vial is suited to pilot studies, individual experimental runs, or protocols with defined single-dose requirements, while the 10-vial KIT format supports larger research programs requiring multiple independent experimental replicates or extended study timelines with consistent inter-vial compound quality. Researchers select format based on total peptide quantity needed across all experimental arms and storage requirements for unused portions.